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Research
Breast cancer is a common disease and a lead­
ing cause of cancer deaths in women (Bray 
et al. 2004; Parkin et al. 2005). However, 
the etiology of breast cancer remains incom­
pletely defined. Evidence indicates that both 
endocrine and environmental factors play 
mechanistic roles in female breast cancer 
(Bray et al. 2004), and estrogenic hormones 
are implicated as major determinants of 
breast cancer risk (Bernstein 2002; Bray et al. 
2004). Endogenous estrogens impact nor­
mal breast growth and development, increas­
ing proliferation of critical cell populations, 
whereas exogenous, pharmaco  logic estrogens 
and xeno  estrogens likely contribute to accu­
mulated breast cancer risk (Bernstein 2002; 
Bray et al. 2004). However, classical estrogens 
alone cannot account for all cases of human 
breast cancer (Coyle 2004). 
Cadmium is a toxic metal and common 
environmental contaminant [International 
Agency for Research on Cancer (IARC) 1993; 
Waalkes 2003]. A human lung carcinogen, 
cadmium has several other target sites in 
rodents, including tissues considered endocrine 
sensitive (IARC 1993; Waalkes 2003). Recent 
data indicate that human cadmium exposure 
may be associated with female breast cancer 
(McElroy et al. 2006), although this initial, 
hypothesis­forming work does not allow for 
establishment of definitive causality. There are 
no corollary data showing carcino  genic activity 
for cadmium in female rodent mammary tis­
sue, but it can cause mammary gland prolifera­
tion in mice (Johnson et al. 2003). Additional 
studies, including in vitro cancer model   
studies, are critical to clarify any role for cad­
mium in this important and deadly disease. 
Cadmium probably acts in all stages of the 
oncogenic process, and acts through multiple, 
nonexclusive mechanisms such as oxidative 
stress, oncogene activation, apoptotic by­
pass, and altered DNA methylation (Waalkes 
2003). Recently, it was proposed that cad­
mium acts as a metallo  estrogen via inter  actions 
with estrogen receptor­α (ER­α), stimulat­
ing downstream estrogen­related processes 
(Garcia­Morales et al. 1994; Johnson et al. 
2003; Stoica et al. 2000). This has led to fears 
that cadmium could act as an xeno  estrogen in 
estrogen­related cancers such as breast cancer 
(Darbre 2006). It is suspected that a critical 
early event in many breast cancers is consti­
tutive activation of the ER­α (Zhang et al. 
2005). Data indicating that human cadmium 
exposure may be a risk factor in breast cancer 
(McElroy et al. 2006) support a concern but 
do not actually address mechanism. Indeed, 
the theory that cadmium is metallo  estrogenic 
has not been fortified by actual data associ­
ating it with acquired malignant phenotype 
in vivo, such as breast tumors in animals, or 
in vitro, such as malignantly transformed 
breast cells. Other researchers have found that 
cadmium lacks strong estrogenic activity or 
actually inhibits ER (Le Guével et al. 2000; 
Silva et al. 2006). We found little evidence 
of ER­α activation in vivo or in vitro by cad­
mium (Coppin JF, Waalkes MP, unpublished 
data). It is evident that cadmium can act 
through various non–estrogen­related mech­
anisms, and several mechanisms can occur 
simultaneously. Further, breast cancer is not 
always a disease that is absolutely estrogen 
dependent (Coyle 2004). 
Given the importance of female breast can­
cer, the emergence of data indicating that cad­
mium may be a risk factor and the unresolved 
proposal that this could occur through a met­
alloestrogenic mechanism both clearly indicate 
that additional research is needed, including 
research using in vitro carcino  genesis model 
systems. Thus, it was our goal to investigate the 
role of ER in a cell model of cadmium­induced 
breast cancer. We examined the malignant 
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Ba c k g r o u n d: Breast cancer has recently been linked to cadmium exposure. Although not uni-
formly supported, it is hypothesized that cadmium acts as a metalloestrogenic carcinogen via the 
estrogen receptor (ER). Thus, we studied the effects of chronic exposure to cadmium on the normal 
human breast epithelial cell line MCF-10A, which is ER-negative but can convert to ER-positive 
during malignant transformation. 
Me t h o d s : Cells were continuously exposed to low-level cadmium (2.5 µM) and checked in vitro 
and by xenograft study for signs of malignant transformation. Transformant cells were molecularly 
characterized by protein and transcript analysis of key genes in breast cancer. 
re s u l t s: Over 40 weeks of cadmium exposure, cells showed increasing secretion of matrix metallo-
proteinase-9, loss of contact inhibition, increased colony formation, and increasing invasion, all 
typical for cancer cells. Inoculation of cadmium-treated cells into mice produced invasive, metastatic 
anaplastic carcinoma with myoepithelial components. These cadmium-transformed breast epithelial 
(CTBE) cells displayed characteristics of basal-like breast carcinoma, including ER-α negativity 
and HER2 (human epidermal growth factor receptor 2) negativity, reduced expression of BRCA1 
(breast cancer susceptibility gene 1), and increased CK5 (cytokeratin 5) and p63 expression. CK5 
and p63, both breast stem cell markers, were prominently over  expressed in CTBE cell mounds, 
indicative of persistent proliferation. CTBE cells showed global DNA hypomethylation and c-myc 
and k-ras over  expression, typical in aggressive breast cancers. CTBE cell xenograft tumors were also 
ER-α negative. 
co n c l u s i o n s: Cadmium malignantly transforms normal human breast epithelial cells—through a 
mechanism not requiring ER-α—into a basal-like cancer phenotype. Direct cadmium induction of a 
malignant phenotype in human breast epithelial cells strongly fortifies a potential role in breast cancer.
key w o r d s : basal-type, breast cancer, cadmium, estrogen receptor, malignant transformation 
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transformation of human normal breast epi­
thelial MCF­10A cells after chronic, low­level 
cadmium exposure in vitro. MCF­10A cells are 
frequently used as a normal control in breast 
cancer studies and are considered negative for 
ER­α and ER­β, but they can show ER activa­
tion with malignant transformation. The capa­
bility to directly trigger a malignant pheno  type 
in human breast epithelial cells would signifi­
cantly fortify emerging data on the human 
breast as a target of cadmium carcino  genesis.
Materials and Methods
Cells and cell culture. MCF­10A cells, 
derived from normal human breast epithe­
lium and immortalized but non  tumorigenic 
(Soule et al. 1990), were grown in a base 
medium (MEGM Bullet Kit; Cambrex, East 
Rutherford, NJ), with all additives supplied 
in the kit except cholera toxin. Cultures were 
incubated at 37°C in 5% CO2 in a humidi­
fied atmosphere and passed weekly. Cells were 
exposed continuously to 2.5 µM cadmium 
(CdCl2; purity 99%; Sigma, St. Louis, MO) 
for up to 40 weeks. We used cultures grown 
in cadmium­free medium as passage­matched 
controls. Once malignant transformation was 
established by formation of xeno  graft tumors, 
they were desig  nated cadmium­transformed 
breast epithelial (CTBE) cells. 
We used untreated MCF­7 human breast 
cancer cells as positive controls for ER­α and 
ER­β protein and SKBR3 human breast can­
cer cells (Chrestensen et al. 2007) as positive 
controls for HER2 (human epidermal growth 
factor receptor 2) protein. 
Matrix metalloproteinase-9. As an indica­
tion of malignant phenotype, secreted matrix 
metalloproteinase­9 (MMP­9) activity was 
assessed as described (Benbrahim­Tallaa et al. 
2005) during cadmium exposure. Activity 
was measured in conditioned media by zymo­
graphic gels, and quantitation was based on 
control values set at 100%.
In vitro invasion. We examined the effect 
of cadmium on in vitro invasive ability using 
a modified Boyden blind­well chamber assay 
(Tokar and Webber 2005). Data were based 
on control cells set at 100%.
Colony formation. We assessed effects of 
chronic cadmium exposure on cellular ability 
to form colonies when plated in soft agar as 
described by Tokar and Webber (2005). Data 
were normalized to control cells set to 100%.
Xenograft tumorigenicity. Animal care 
was provided in accordance with the Guide 
for the Care and Use of Laboratory Animals 
(Institute of Laboratory Animal Resources 
1996). The animals were treated humanely 
and with regard for alleviation of suffering. 
Mice were housed under conditions of con­
trolled temperature, humidity, and light cycle. 
For the xenograft study [National Cancer 
Institute (NCI)­Frederick Animal Facility], 
1 × 106 control cells or chronic cadmium­
treated (40 weeks) cells were inoculated 
bilaterally under the renal capsules (50 µL/
capsule) of 10 female nude (NCr­nu) mice 
(NCI­Frederick) per cell­treatment group. 
Mice were palpated twice daily for signs of 
tumors and killed when tumors developed 
or at 6 months after inoculation. A complete 
necropsy was performed, and obvious tumors, 
both kidneys, and all abnormal tissues were 
fixed in 10% buffered formalin. Tissues were 
embedded in paraffin, sectioned, stained with 
hematoxylin and eosin (H&E), and analyzed 
by light microscopy. 
Gene expression analysis. We identified gene 
expression at the protein level by Western blot 
(Benbrahim­Tallaa et al. 2005). Total protein 
was isolated and electrophoresed on NuPAGE 
4–12% Bis­Tris gel (Invitrogen, Carlsbad, 
CA) and transferred to nitro  cellulose mem­
branes following the manufacturer’s instruc­
tions. Immunoblots were performed using 
antibodies for human k­ras, c­myc, and ER­β 
(at 1:1000 dilution; all from Calbiochem, San 
Diego, CA), CK5 (cytokeratin 5; at 1:1,000 
dilution; Abcam, Cambridge, MA), human 
ER­α (1:100; Calbiochem), HER2 (1:500; 
Santa Cruz Biotechnology, Santa Cruz, CA), 
metallothionein (MT1/2; 1:200; Santa Cruz 
Biotechnology), or ΔNp63 (p63; 1:100; Santa 
Cruz Biotechnology). We then used horse  radish 
peroxidase–conjugated anti­rabbit secondary 
antibodies and anti­mouse secondary anti­
bodies (1:5,000; Amersham, Pittsburgh, PA) 
with the SuperSignal West Pico chemilumines­
cent substrate (Pierce, Rockford, IL). Signals 
were visualized by Hyperfilm (Amersham), and 
densitometric analysis was performed using 
Quantity One software (Bio­Rad, Hercules, 
CA). The data were normalized to individual 
β­actin and adjusted to control as 100%.
We determined gene expression at the tran­
script level by reverse transcription­polymerase 
chain reaction (RT­PCR) as described previ­
ously (Benbrahim­Talla et al. 2005). The data 
were normalized to individual β­actin level and 
Figure 1. Chronic cadmium exposure induces a cancer phenotype in human breast epithelial cells 
exposed to 2.5 µM cadmium for up to 40 weeks compared with passage-matched, untreated control cells. 
(A) Active MMP-9 secretion during cadmium exposure. (B) Loss of contact inhibition at 40 weeks of cad-
mium exposure as indicated by formation of foci of cell mounding (arrows; bottom) that were rarely seen in 
control (top). Bars = 100 µm. (C) Increased colony formation in soft agar with chronic cadmium exposure. 
(D) Increased invasive ability with cadmium exposure. Numerical data are expressed as a percentage of 
control (set to 100%) ± SE. 
*Significantly different from control. 
250
200
150
100
50
0
250
200
150
100
50
0
500
400
300
200
100
0
M
M
P
-
9
 
s
e
c
r
e
t
i
o
n
 
(
p
e
r
c
e
n
t
 
o
f
 
c
o
n
t
r
o
l
)
C
o
l
o
n
y
 
f
o
r
m
a
t
i
o
n
 
(
p
e
r
c
e
n
t
 
o
f
 
c
o
n
t
r
o
l
)
I
n
v
a
s
i
o
n
 
(
p
e
r
c
e
n
t
 
o
f
 
c
o
n
t
r
o
l
)
01 0
Control
* *
20 weeks 40 weeks 20 weeks 40 weeks Control
Cadmium exposure (weeks)
20 30 40
*
*
*
*
*
*
*
*
*
Control
Cadmium
Cadmium
ControlCadmium-induced breast cell transformation
Environmental Health Perspectives  •  v o l u m e  117 | n u m b e r 12 | December 2009  1849
adjusted to control as 100%. All primers were 
synthesized by Invitrogen. The primers were 
as follows: 
β-actin 
forward: CCCAGATCATGT  TTGAGACCT 
reverse: GAGTCCATCACGATGCCAGT
BRCA1 (breast cancer susceptibility gene 1) 
forward: GCTCTTCGCGTTGAAGAAGT 
reverse: TGTGGAGACAGGTTCCTTGA
c-myc  
forward: CTCCCTCCACTCGGAAGGA 
reverse: CGGTTGTTGCTGATCTGTCTCA
K-ras  
forward: CCCAGGTTCAAGCGATTCTC 
reverse: GAGTGTAGTGCACACGC  CTGTAA
CK5  
forward: GTAGCAGCTCCAGCGTCAAAT 
reverse: TTGGAAGGCAGTGACTTGCA
p63  
forward: CCCCAAGCAGTGCCTCTACA 
reverse: GGTGAATCGCACAGCATCAA
aromatase (CYP19A)  
forward: CTGGCCTTTTTCTCTTGGTG  
reverse: ATCCCCATCCACAGGAATCT.
Global DNA methylation. We deter­
mined global DNA methylation by the methyl 
acceptance assay, as described previously 
(Benbrahim­Tallaa et al. 2005), at 0, 20, and 
40 weeks of cadmium exposure. 
Expression of p63 and CK5. Cells were 
plated on coverglass chamber slides, grown to 
confluence, and fixed with acetone:methanol 
(1:1) for 2 min. Cells were then incubated with 
primary antibodies (1:200 dilution) against 
ΔNp63 (p63; Santa Cruz Biotechnology) 
or CK5 (Abcam) for 2 hr, washed with PBS 
(3 times 15 min), incubated with AlexaFluor 
488 and AlexaFluor 569 fluorescent­conju­
gated secondary anti  bodies (Molecular Probes; 
Invitrogen, Carlsbad, CA) for 1 hr, and then 
washed with PBS (3 times, 15 min). DAPI 
(4´,6­diamidino­2­phenylindole; 1:1,000) was 
added for 5–10 min, and cells were rinsed with 
PBS (3 times, 15 min). Images were imme­
diately taken using a DP72 camera and IX71 
microscope (Olympus, Center Valley, PA). 
Tumor ER-α. We used CTBE cell– 
generated xeno  graft tumors for immuno­
histochemical analysis of ER­α protein. 
For a positive control, we used an ER­α–
positive human breast tumor paraffin block 
(PanTomics, Richmond, CA). We used poly­
clonal antibody against human ER­α as the 
primary antibody (at a dilution of 1:1,000) and 
a streptavidin­conjugated secondary antibody. 
Antibody binding was visualized with an avid­
in­biotin­peroxidase kit (VECTASTAIN Elite 
ABC Kit; Vector Laboratories, Burlingame, 
CA) with diaminobenzidine as the chromagen 
and hematoxylin as a nuclear counterstain. As a 
control, the primary antibodies were omitted.
Statistical analysis. All data except 
tumor incidence are presented as mean ± SE 
from three or more independent samplings. 
Significance was determined by Student’s t­test, 
by analysis of variance followed by Dunnett’s 
multiple comparison test, or by Fisher exact 
test as appropriate, with p ≤ 0.05 considered 
significant. 
Results
Cadmium-exposed breast cells acquire a cancer 
phenotype. We assessed the ability of chronic, 
low­level cadmium to induce transformation 
in the MCF­10A ER­negative human breast 
epithelial cell line using various measure­
ments including MMP­9, an enzyme secreted 
to degrade the extra  cellular matrix and facili­
tate tumor cell invasion. A marked, progres­
sive increase in the secretion of active MMP­9 
occurred with cadmium exposure (Figure 1A). 
By 40 weeks of exposure, cadmium­exposed 
cells also started forming cell mounds when 
confluent (Figure 1B); this mounding indicates 
a loss of contact inhibition, which allows cells 
to continue to divide and form multiple hori­
zontal layers, a common occurrence with can­
cer cells. Although mounding was common in 
cadmium­treated cells, it was seldom observed 
in control cells. Cadmium­treated cells even 
formed mounds when subconfluent, which we 
did not observe in controls (data not shown). 
Cadmium also markedly increased colony for­
mation in soft agar by 40 weeks of exposure 
(Figure 1C), which is typical of cancer cells and 
is thought to reflect anchorage­independent 
growth of tumor­initiating/cancer stem cells 
(Stingl et al. 2006; Tokar and Webber 2005). 
Invasive ability was also greatly increased by 
40 weeks of cadmium exposure (Figure 1D), a 
common characteristic of cancer cells. 
Cadmium-exposed breast cells acquire a 
malignant phenotype. Compelling evidence 
that cadmium had triggered a malignant 
pheno  type was provided when malignant 
tumors formed in mice that had been inoc­
ulated under the renal capsule with cells 
chronically exposed to cadmium (40­week 
exposure) (Figure 2A). The CTBE cells pro­
duced highly aggressive carcinoma within 
as little as 1 month. No tumors arose after 
inoculation with control cells. CTBE cells 
produced highly malignant, invasive, ana­
plastic carcinoma with myo  epithelial com­
ponents containing epithelial, mesenchymal, 
and undifferentiated cells (Figure 2B). CTBE 
cell tumors showed metastatic potential, 
as exemplified by a metas  tasis to a regional 
lymph node (Figure 2C). Invasive carcino­
mas make up approximately 85% of all diag­
nosed human breast cancers, and regional 
node metastasis is common with aggressive 
breast tumors.
CTBE cells have basal-like malignant 
breast tumor characteristics. Various breast 
cancer phenotypes have been defined based 
on molecular pathology, including the myo­
epithelial basal­like carcinoma of the breast 
that is characterized as ER­negative and 
HER2­negative with increased expression of 
CK5 and p63 (Fadare and Tavassoli 2007; 
Yehiely et al. 2006). Indeed, the ER­negative 
MCF­10A cells remained negative for ER­α 
and ER­β protein when they became CTBE 
cells (Figure 3A). ER­α and ER­β proteins 
were undetectable in CTBE cells com­
pared with a positive control breast cancer 
cell line (MCF­7). Also, genes downstream 
of ER­α driven by estrogens were not acti­
vated by chronic cadmium in CTBE cells, 
including pS2 (data not shown). Control and 
CTBE cells also showed no HER2 protein 
(Figure 3A) compared with an HER2­positive 
breast cancer line (SKBR3). In contrast, MT, 
which is over  expressed in ER­negative breast 
cancers, was relatively low in control cells but 
markedly increased in CTBE cells (Figure 3B). 
Figure 2. Tumor formation resulting from inoculation of CTBE cells into nude mice. (A) Tumor formation 
rate during 6 months after inoculation of CTBE or control cells under the renal capsules of 10 mice/group. 
(B) Representative section of an anaplastic carcinoma invading the normal kidney, which formed after CTBE 
inoculation; bar = 50 µm. The tumor is highly aggressive, with areas of epithelial, mesenchymal, and undiffer-
entiated cells. (C) A representative metastasis to a peritoneal lymph node of a carcinoma produced by CTBE 
cell inoculation; bar = 500 µm. 
*Significantly different from control. 
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Further, MCF­10A cells are considered to 
have normal BRCA1 function (You et al. 
2004), yet BRCA1 expression was suppressed 
in CTBE cells (Figure 3C). 
Both CK5 and p63 were overexpressed 
in CTBE cells (Figure 4A). CK5 and p63 are 
considered stem cell markers in breast tissue, 
and p63 may act as an oncogene. Foci of cell 
mounding, common in CTBE cells but rare 
in controls, indicate cells with loss of contact 
inhibition that maintain active proliferation. 
When we assessed foci for p63 and CK5, we 
found little or no expression in an uncom­
mon foci from control cells (Figure 4B), but 
the much more commonly occurring CTBE 
cell mound foci showed intense expression for 
both p63 and CK5 protein in association with 
the mound (Figure 4C). 
CTBE cells acquire characteristics of 
aggressive malignant breast cancer cells. 
Compared with control cells, CTBE cells 
showed marked increases of both K-ras 
(Figure 5A) and c-myc (Figure 5B), oncogenes 
that are commonly over  expressed in aggressive 
breast cancers (Eckert et al. 2004; Jamerson 
et al. 2004). In breast cancers, DNA hypo­
methylation decreases progressively as tumor 
grade worsens (Agrawal et al. 2007), and 
CTBE cells showed a significant and progres­
sive increase in global DNA hypomethylation 
with cadmium exposure (Figure 5C).
Xenograft tumors remain ER-α negative. 
The remarkable cellular expansion in going 
from the tissue culture environment to a 
xeno  graft tumor could provide a stimulus for 
acquired expression of genes not seen in vitro, 
such as ER­α. However, analysis of CTBE­
induced xeno  graft tumors showed minimal 
ER­α protein in the tumor cells (Figure 6A) 
compared with strong nuclear staining in a 
human breast carcinoma known to be ER­α 
positive (Figure 6B). A lymph node metasta­
sis from a CTBE­formed tumor also showed 
minimal ER­α protein (Figure 6C).
Aromatase in CTBE cells. Cadmium 
may have indirectly provided MCF­10A cells 
with estrogen via increased aromatase activ­
ity. However, transcript analysis indicated 
that CTBE cells showed no higher levels 
Figure 4. Expression of genes in CTBE cells typical for basal-like human breast cancer phenotype and/or breast stem cells. (A) Protein expression for CK5 and p63 
expressed as a percentage of control. Fluorescent microscopy was used to determine localization of stem cell marker protein expression in (B) control cells and 
(C) CTBE cells. Expression of CK5 (green) and p63 (red) were clearly co-localized to foci of cell mounding (yellow) in CTBE cells and, in comparison, barely detectable 
in similar structures from control cells. DAPI was used as a nuclear stain to show similar number of viable cells. Top images (gray) are relief contrast. Bars = 25 µm. 
*Significantly different from control. 
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Figure 3. Expression of ER-α, ER-β, HER2, BRCA1, and MT in CTBE cells. (A) ER-α, ER-β, and HER2 protein 
levels showing clear negativity of control MCF-10A and CTBE cells. The positive controls were ER-α- and 
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trol and CTBE cells. (B) MT protein showing relatively low expression in control but increased expression 
in CTBE cells. (C) BRCA1 protein and transcript in CTBE and control cells. The data for MT and BRCA1 are 
expressed as a percentage of control (set to 100%; ± SE). 
*Significantly different from control. 
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(145 ± 34% of control; n = 3) than passage­
matched control cells (100 ± 21%).
Discussion
Environmental factors may account for a large 
portion of human breast cancers, perhaps 
approaching 60% (Coyle 2004). Established 
risk factors such as exogenous estrogens account 
for a significant portion of this risk (Bernstein 
2002; Bray et al. 2004) but do not explain 
the remainder (Coyle 2004). The increasing 
incidence and geographic variation of human 
breast cancer has begun to focus attention on 
the etiologic potential of other environmental 
factors (Coyle 2004). Cadmium, a common 
environ  mental pollutant, may be such a factor 
(McElroy et al. 2006) and is noteworthy as a 
biologically persistent and cumulative metal 
(IARC 1993; Waalkes 2003). Unusually high 
levels of cadmium are found in human breast 
tissue, perhaps indicating specific binding 
(Antilia et al. 1996), although inter  individual 
levels vary widely. Cadmium was linked to 
human breast cancer in a recent population­
based, case–control study (McElroy et al. 
2006). Based on urinary cadmium, both breast 
cancer risk and tumor aggressiveness increased 
with increasing exposure (McElroy et al. 2006). 
This is consistent with our data, where cad­
mium in vitro both induced malignant trans­
formation and produced highly aggressive cells, 
as the molecular pheno  type of the CTBE cells 
equates to a cancer of poor prognosis (Fadare 
and Tavassoli 2007; Yehiely et al. 2006). The 
direct triggering of an acquired malignant phe­
notype by cadmium in human breast epithelial 
cells strongly supports the emerging epidemio­
logic data indicating a role for cadmium in 
human breast cancer (McElroy et al. 2006). 
This present study demonstrated that 
ER­negative human breast epithelial cells 
undergo transformation with chronic cad­
mium exposure. However, CTBE cells remain 
ER­negative after acquisition of malignant 
phenotype in vitro and even after production 
of xenograft tumors in vivo. Indeed, cadmium 
produced an apparent basal­like breast cancer 
phenotype, including ER negativity, HER2 
negativity, reduced BRCA1 expression, and 
increased expression of p63 and CK5, all note­
worthy charac  teristics of basal­like human 
breast cancer pheno  type (Fadare and Tavassoli 
2007; Liu et al. 2008; Ribeiro­Silva et al. 
2005; Yehiely et al. 2006). Basal­like breast 
cancers clinically show both poor relapse­free 
and poor survival rates (Fadare and Tavassoli 
2007; Yehiely et al. 2006), and the anaplas­
tic xenograft tumors formed with CTBE cells 
are consistent with an aggressive tumor with 
poor prognosis. One mechanism proposed 
for cadmium is that it acts through actions at 
ER­α that mimic estrogens, thereby chroni­
cally activating pathways that predispose to 
estrogen­related cancer (Garcia­Morales et al. 
1994; Johnson et al. 2003; Stoica et al. 2000). 
The MCF­10A cells used in this study can be 
treated in various ways to undergo transforma­
tion with the emergence of stimulated ER­α 
expression as the probable basis for the malig­
nant conversion (Shekhar et al. 1998; Zhang 
et al. 2005). MCF­10A cells can show acti­
vation of genes not seen in basal­like breast 
cancer phenotypes, such as HER2, with 
acquired malignant potential (Li et al. 2004). 
MCF­10A cells are fully capable of reversing 
their ER negativity during acquired malignant 
phenotype (Shekhar et al. 1998; Zhang et al. 
2005). A key early event in estrogen­dependent 
breast cancers is activation of ER­α, which 
can occur with MCF­10A cell transforma­
tion (Zhang et al. 2005). Yet, in our model, 
MCF­10A cells were ER­negative at the onset, 
remained so in vitro after cadmium­induced 
malignant transformation, and continued to 
be ER­negative after forming xeno  graft carci­
nomas. Cadmium has a variety of possible car­
cinogenic mechanisms, but from this work it 
appears unlikely that metallo  estrogenic actions 
through ER were a major factor. Nonetheless, 
it is possible that cadmium may have metallo­
estrogenic effects in some instances, and a 
recent epidemiologic study associated dietary 
cadmium with endometrial cancer, another 
site considered estrogen­related (Akesson et al. 
2008). However, assumption of mechanism 
without clear and compelling data may be 
unwarranted with carcinogens like cadmium, 
which clearly has multiple possible mechanisms 
(IARC 1993; Waalkes 2003). 
Several studies have shown that human 
breast tissue concentrates cadmium, and this 
is exaggerated in cancerous tissue (Antila 
et al. 1996; Ionescu et al. 2006; Rydzewska 
et al. 2004; Strumylaite et al. 2008). The 
metal­binding protein MT avidly binds cad­
mium and likely accounts for its long tissue­ 
residence time (Cherian et al. 2003). In 
humans, breast tumor MT over  expression is 
associated with a poorer prognosis (Jin et al. 
2004). A remarkably clear correlation exists in 
breast tumors between MT over  expression and 
poor ER expression (El Sharkawy and Farrag 
2008), indicating that increased MT may be 
another basal­like phenotype marker. Tissues 
often accumulate cadmium associated with 
MT (Cherian et al. 2003). Thus, whatever 
mechanisms may operate in the breast, this 
MT over  production would toxico  kinetically 
favor cadmium­induced tumor formation by 
enhancing the metals accumulation. 
Figure 5. Oncogene activation and global DNA hypomethylation during acquired malignant phenotype in 
CTBE cells. (A) K-ras expression. (B) c-myc expression. (C) DNA methylation. Protein or transcript data are 
expressed as percentage of control (set to 100% ± SE). Note broken scale in (C). 
*Significantly different from control. 
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Figure 6. Immunohistochemical analysis for ER-α in xenograft tumors produced by CTBE cell inoculation 
(A, C) and a positive control (B). (A) Example of a tumor formed by inoculation of CTBE injection, showing 
minimal ER-α protein in the cells of the tumor. (B) A commercially available, known ER-α-positive human 
breast carcinoma showing strong, nuclear staining (brown). (C) A lymph node metastasis from a CTBE-
formed tumor showing minimal ER-α protein. Bars = 100 µm. Benbrahim-Tallaa et al.
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Both p63 and CK5 expression were mark­
edly increased in CTBE cells. CK5 and p63 
are both considered basal­like breast carcinoma 
markers (Fadare and Tavassoli 2007; Yehiely 
et al. 2006) and markers for breast stem cells 
(Boecker and Buerger 2003; Ribeiro­Silva et al. 
2005). It appears that p63 functions to pre­
serve adult breast stem cells, facilitating replica­
tion and regeneration, possibly by restricting 
proliferation from an undifferentiated state 
(Ribeiro­Silva et al. 2005). Similarly, CK5­
positive cells likely represent undifferentiated 
adult stem cells with potential to differentiate 
into glandular or myoepithelial cells (Boecker 
and Buerger 2003). CTBE cells show increased 
expression of both p63 and CK5, particularly 
in areas of cell mounding (active proliferation), 
indicating the over  production of stemlike 
cells that have lost appropriate differentiation 
capacity during malignant transformation. An 
emerging hypothesis is that breast stem cells are 
critical targets of carcinogens and that blocked 
differentiation is likely a major pathway to can­
cer (Dontu et al. 2005). The fact that CTBE 
cells over  express stem cell markers and produce 
a poorly differentiated, aggressive anaplastic 
xeno  graft carcinoma is consistent with this 
hypothesis. Reduced expression of BRCA1 
also strongly correlates with over  expression of 
both CK5 and p63 (Ribeiro­Silva et al. 2005). 
BRCA1 is considered to be a breast tumor sup­
pressor gene, and reduced expression or loss of 
function is associated with ER­negative basal­
type breast cancers (Liu et al. 2008; Ribeiro­
Silva et al. 2005). Accumulating data indicates 
that BRCA1 regulates stem/progenitor cell fate 
in the breast (Liu et al. 2008; Ribeiro­Silva 
et al. 2005), and loss of function or suppressed 
BRCA1 expression may lead to dys  regulated 
stem cell self­renewal or differentiation lead­
ing to basal­type breast carcinomas (Liu et al. 
2008). Loss of BRCA1 function can cause the 
accumulation of genetically unstable breast 
stem cells, providing critical targets for further 
carcinogenic events (Liu et al. 2008). Thus, 
CTBE cells showed both p63 and CK5 over­
expression together with a significant loss of 
BRCA1 expression and ER negativity, all con­
sistent basal breast cancer phenotype (Liu et al. 
2008; Ribeiro­Silva et al. 2005), which may 
indicate a loss of differentiation capacity during 
the acquisition of basal malignant phenotype.
Further studies are needed to elucidate the 
mechanisms by which cadmium may cause 
breast cancer. However, in the present study, 
cadmium malignantly transformed a breast 
epithelial cell, producing various molecular 
hallmarks of a basal­like breast cancer, includ­
ing ER negativity. Thus, actions for cadmium 
as a metallo  estrogen in this case are unlikely. 
It is possible that cadmium acted by produc­
ing altered DNA methylation status, thereby 
altering expression of key genes, including 
oncogenes, as seen in prior work with other 
cell transformation systems (Qu et al. 2005; 
Takiguchi et al. 2003). It also appears that 
cadmium transformation distorted stem cell 
population dynamics, a common occurrence 
in onco  genesis (Wicha et al. 2006). Defining 
the exact mechanism of action for cadmium 
in the present case will require additional 
work. Regardless of the precise mechanism, 
the direct triggering of malignant phenotype 
by cadmium in human breast epithelial cells 
unambiguously supports a role for the metal 
in human breast cancer. 
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